Venmax Drugs & Pharmaceuticals P/E Ratio
Current P/E Ratio
89.11
High Valuation
Very High - High growth expectations or significantly overvalued
Venmax Drugs & Pharmaceuticals (VENMAX) P/E ratio is 89.11 (High), EPS (TTM) ₹0.21, current price ₹16.73 on BSE — Very High - High growth expectations or significantly overvalued. For live price, revenue and the complete fundamental profile, see VENMAX share price screener.
Current Valuation Metrics
P/E Ratio
89.11
Current Price
₹16.73
EPS (TTM)
₹0.21
Exchange
BSE
Valuation Signal
Signal
Overvalued
Sector Context
Sector Average
55.3
Sector Median
30.43
Sector Rank
#11 of 195
Sector Percentile
5.6%
VENMAX P/E Ratio — Valuation Signal & Historical Context
Venmax Drugs & Pharmaceuticals P/E 89.11 — signal: Overvalued. Read Venmax Drugs & Pharmaceuticals dividend policy for the complete payout history and dividend yield track record.
- Stock appears overvalued with PE of 89.11, suggesting caution for new investments
- Trading at premium to sector average PE of 55.3
VENMAX vs Healthcare Peers — P/E Ratio Comparison
Venmax Drugs & Pharmaceuticals P/E 89.11 vs Healthcare average 55.3, median 30.43 — range 2.86–712.0.
Sector Average
55.3
Sector Median
30.43
Lowest P/E
2.86
Highest P/E
712.0
Companies
195
| Company | Symbol | P/E Ratio | Market Cap (₹ Cr) | Valuation |
|---|---|---|---|---|
| Murae Organisor | MURAE | 2.86 | ₹41 | Low |
| Phaarmasia | PHRMASI | 3.29 | ₹53 | Low |
| Colinz Laboratories | COLINZ | 3.6 | ₹10 | Low |
| Sun Pharma Advanced Rese… | SPARC | 4.05 | ₹6,404 | Low |
| Sunrest Lifescience | SUNREST | 4.08 | ₹65 | Low |
| Shelter Pharma | SHELTER | 4.85 | ₹44 | Low |
| GKB Ophthalmics | GKB | 5.94 | ₹33 | Low |
| JFL Life Sciences | JFLLIFE | 6.44 | ₹86 | Low |
| Dipna Pharmachem | DPL | 6.52 | ₹18 | Low |
| Royal Sense | ROYAL | 7.11 | ₹51 | Low |